Drug Database
Back to search

Switzerland· 63165002

Zyclara, Crème

A imiquimod product containing imiquimodum, registered in Switzerland by Viatris Pharma GmbH and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 16 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC D06BB10

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedZyclara, CrèmeATCD06BB10REGISTER NO.63165002PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about imiquimodumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Imiquimod is registered in 16 of 19 countries.

Countries holding a registration under ATC D06BB10 (imiquimod), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 10 of them publish a price we can compare per daily dose
Search imiquimod products by name

Imiquimod · ATC D06BB10

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Swissmedic (Switzerland)
Active substance
imiquimodum
Manufacturer
Viatris Pharma GmbH
Country
Switzerland (CH)
ATC code
D06BB10
ATC class
Imiquimod
Swissmedic category
A
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680631650022
    Btl 28 Stk
    CHF 130.05

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

74 interactions on record for imiquimod.

Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check imiquimod against other medicinesHow interaction checks work

Imiquimod · interactions on record

74 records

  • 1 severe
  • 3 moderate
  • 70 info

Most severe, free to view

  • Aminolevulinic acidL01XD04severe
  • Porfimer sodiumL01XD01moderate
  • MethoxsalenL01XD10moderate
  • VerteporfinS01LA01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Imiquimod in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All imiquimod products

Authorised across Europe · EMA

The same active substance is authorised in 14 EEA countries. Names it is sold under:

  • Austria · Imikeraderm
  • Cyprus · Modiwart
  • Germany · Aksunim, Imikeraderm
  • Spain · Imikeraderm, Imunocare
  • United Kingdom (Northern Ireland) · Bascellex
  • Greece · Modiwart, Quimodia
  • Iceland · Aldara, Zyclara
  • Italy · Imunocare
  • Liechtenstein · Aldara, Zyclara
  • Netherlands · Bascellex
  • Norway · Aldara, Bascellex
  • Poland · Imikeraderm
  • Portugal · Imicare
  • Sweden · Bascellex

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/a6052687-8c1a-47fb-b1ec-1dfe61e0da67
GET /v1/drugs/a6052687-8c1a-47fb-b1ec-1dfe61e0da67?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "imiquimodum 37.5 mg",
  "valid_from": "2015-03-01",
  "limitations": "[{\"description\":\"Zyclara ist angezeigt für die topische Behandlung von klinisch typischer, nicht hyperkeratotischer, nicht hypertropher, sichtbarer oder tastbarer aktinischer Keratose (AK) im Gesicht oder auf der unbehaarten Kopfhaut bei immunkompetenten Erwachsenen, wenn andere topische Behandlungsmöglichkeiten kontraindiziert oder weniger geeignet sind.\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2015-03-01\"}]",
  "galenic_form": "Creme 37.5 mg/g",
  "therapeutic_area": null,
  "sl_inclusion_date": "2015-03-01",
  "self_retention_pct": 10
}
API referenceMCP serverPlans

See everything about imiquimod.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console